New deal for Gestiva
Written on January 15, 2010
KV Pharmaceutical Co. said Monday that it altered the agreement that gave it the rights to Gestiva, a drug intended to prevent premature birth.
In 2008, KV agreed to buy Gestiva from Hologic Inc. in a deal worth $82 million. It paid $7.5 million to Hologic, but the Gestiva assets were not transferred to KV.
KV would have been able to terminate the agreement in mid-February.
Filed in: term.